Blockbusters Lose Patent Protection
In 2011-2014, the terms of patent protection for 35 blockbusters expire
Pharmacy online (www.apteka.ua ) based on the materials of thepharmaletter:
Over 35 blockbuster branded pharmaceuticals to go off-patent in 2011 and 2012
According to the forecasts published on the website thepharmaletter.com , in the next few years, the terms of patent protection for 35 blockbusters, whose total annual sales exceed $209 billion, will expire. Among these drugs are such major brands as Advair™/Seretid™ (fluticasone + salmeterol, GlaxoSmithKline plc), Viagra™/Viagra (sildenafil, Pfizer Inc.), Seroquel™/Seroquel (quetiapine, Astra Zeneca plc), Symbicort™/Symbicort Turbuhaler (budezonide + formoterol, Astra Zeneca plc), Zyprexa™/Ziprexa™(olanzapine, Eli Lilly& Co. Inc.), Singulair™ (montelukast, Merck&Co., Inc."), Lexapro™ (escitalopram, Forest Laboratories Inc.).
The volume of the global generic medicines market is projected to reach USD 135-150 billion by 2015. The research company "BCC Research" estimates the average annual growth rate of this market at the level of 9%.
According to IMS Health estimates, the volume of sales of generic medicines in 8 leading global pharmaceutical markets (USA, Canada, France, Germany, Italy, Spain, Great Britain and Japan) amounted to $62.6 billion by the end of 2009. In the total volume of the US pharmaceutical market in physical terms in 2009, generic drugs accumulated a specific weight of 72%. The total volume of the global generic drugs market in 2011, according to preliminary estimates, could reach $ 100 billion.
Along with the expiration of patent protection for many marketed drugs, the rapid growth of the global generic market will also be facilitated by the reform of healthcare systems aimed at saving budget funds, and as a result, the shift in consumption structure from expensive original medicines to more affordable ones in cases of generic replacement.
In the current situation on the global pharmaceutical market, we can expect a fierce competitive battle of pharmaceutical companies for a promising segment of generic drugs.
Portal "Eternal youth" http://vechnayamolodost.ru
28.01.2011